By continuing to use the site you agree to our Privacy & Cookies policy

New drug for diabetes approved

NICE has approved a drug for treating patients with type 2 diabetes who are intolerant of either metformin, sulphonylurea, thiazolidinediones or dipeptidyl peptidase-4 inhibitors.

Primary care trusts have been ordered by NICE to start funding liraglutide (Victoza), giving 1.2mg daily as a combination treatment. However, it has not approved a 1.8mg dose as the available evidence does not suggest any significant additional benefit.

Have your say

You must sign in to make a comment.

Related Jobs

Sign in to see the latest jobs relevant to you!